Literature DB >> 830196

Pharmacokinetic studies of quinidine in patients with arrhythmias.

K A Conrad, B L Molk, C A Chidsey.   

Abstract

The absorption and disposition of quinidine were measured in nine patients following single oral and intravenous dosing. A new specific chromatographic method was used to measure the drug in plasma and urine. After intravenous administration, the plasma half-life (t1/2beta) was 7.8+/-0.7 h, the volume of distribution (Vd) was 3.0+/-0.5 liters/kg, and the total body clearance was 4.8+/-0.8 ml/min/kg. After oral administration, 87+/-7% (mean+/-SEM) was available to the systemic circulation. Quinidine was removed primarily by hepatic metabolism, with the renal clearance averaging only 1.0+/-0.2 ml/min/kg. Mean quinidine concentrations were estimated in 42 patients on chronic therapy by averaging blood levels during a dosing interval. In patients without heart failure, these corresponded well to mean drug levels predicted from the pharmacokinetic parameters measured after a single intravenous dose, but in patients with heart failure, the values for mean quinidine concentrations were higher than predicted. This suggests that impaired elimination of the drug or a decreased volume of its distribution, or both, may develop in heart failure.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 830196

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  23 in total

1.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

Review 2.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

3.  Pharmacokinetics of quinidine in male patients. A population analysis.

Authors:  C N Verme; T M Ludden; W A Clementi; S C Harris
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

4.  Population pharmacokinetics of quinidine.

Authors:  K Fattinger; S Vozeh; H R Ha; M Borner; F Follath
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

5.  Pharmacokinetics of quinidine related to plasma protein binding in man.

Authors:  D Fremstad; O G Nilsen; L Storstein; J Amlie; S Jacobsen
Journal:  Eur J Clin Pharmacol       Date:  1979-04-17       Impact factor: 2.953

Review 6.  Clinical relevance of pharmacokinetics.

Authors:  G Tognoni; C Bellantuono; M Bonati; M D'Incalci; M Gerna; R Latini; M Mandelli; M G Porro; E Riva
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

7.  Pharmacokinetics of dihydroquinidine in congestive heart failure patients after intravenous quinidine administration.

Authors:  C T Ueda; B S Dzindzio
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

8.  Urinary excretion kinetics of intact quinidine and 3-OH-quinidine after oral administration of a single oral dose of quinidine gluconate in the fasting and non-fasting state.

Authors:  J M St-Onge; G Sirois; M A Gagnon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983 Oct-Dec       Impact factor: 2.441

9.  Bioavailability of quinidine in congestive heart failure.

Authors:  C T Ueda; B S Dzindzio
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

Review 10.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.